21:04 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Reata reports Phase II data for bardoxolone methyl in CKD

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from 30 patients with chronic kidney disease (CKD) caused by Alport syndrome in the open-label Phase II portion of the Phase II/III CARDINAL trial showing that once-daily oral bardoxolone...
22:44 , Jul 24, 2017 |  BC Extra  |  Clinical News

Reata gains as bardoxolone study moves to Phase III

Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $4.37 (14%) to $35.47 on Monday after saying it will move ahead to the Phase III portion of the Phase II/III CARDINAL study of bardoxolone methyl (RTA 402) to treat...
08:00 , Mar 10, 2016 |  BC Innovations  |  Targets & Mechanisms

Brown fat heats up

While FGF21 is the clear frontrunner target for stimulating brown and beige fat, players in the seven year-old field believe there's room for plenty more runners in the race. Since the start of the year,...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

GSK2998728: Additional Phase II data

Additional data from 3 patients with TTR-related cardiomyopathy who completed 12 months of dosing in an investigator-initiated, open-label, U.S. Phase II trial showed that once-weekly 300 mg subcutaneous ISIS-TTRRx led to a mean reduction of...
08:00 , Dec 4, 2014 |  BC Innovations  |  Tools & Techniques

Roche's heart for diabetes

Building on cardiomyocytes generated from iPS cells by Cellular Dynamics International Inc., Roche scientists have developed a cell-based model of diabetic cardiomyopathy for use in discovery screening.1 The cells have the metabolic and physiological features...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

Demcizumab: Additional Phase Ib data

Additional data from 22 evaluable patients in an open-label, dose-escalation, international Phase Ib trial showed that first-line treatment with IV demcizumab plus gemcitabine with Abraxane nab-paclitaxel led to a clinical benefit rate (CBR) of...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Meritas BNP test regulatory update

Trinity said it received CE Mark approval for its Meritas BNP test for B-type natriuretic peptide (BNP; NPPB), a marker for heart failure. The point-of-care blood test delivers results in 10 minutes. Trinity...
07:00 , Jul 21, 2014 |  BioCentury  |  Strategy

AbbVie's plan B

Clinical setbacks and a rapidly evolving HCV landscape have left AbbVie Inc. less insulated from potential biosimilar competition for blockbuster Humira adalimumab. Now that Shire plc has decided to accept AbbVie's takeout bid, the specialty...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Bardoxolone methyl: Phase II started

Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.), which spun out its pharmaceutical business into AbbVie in January 2013, gained rights from Reata to bardoxolone methyl outside the U.S. and certain Asian markets under a 2010 deal...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

Demcizumab: Additional Phase Ib data

Data from 6 evaluable patients with locally advanced or metastatic pancreatic cancer in an open-label, dose-escalation, international Phase Ib trial showed that first-line treatment with IV demcizumab plus gemcitabine and Abraxane nab-paclitaxel led to...